Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Completed; Phase 1

Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System

Treatments: Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

Study type: Interventional

Funder types: Other

Identifiers

NCT00877110

09-011

MSKCC09011 FDR004128 (Other Grant/Funding Number)

Details and patient eligibility

About

Funding Source - FDA OOPD FDR004128

The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8. The NK cells must come from a family member who shares half of the HLA proteins which are immune proteins important in transplant. NK cells are a type of white blood cell. They can recognize and kill abnormal cells in the body and can work together with antibodies to kill target cells. The antibody 3F8 specifically recognizes a protein present on the target cancer cell.

Enrollment: 71 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the MSKCC Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
• High-risk NB as defined by risk-related treatment guidelines and the International NB Staging System,57 i.e., stage 4 with (any age) or without (>365 days of age) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4S.
• Patients must have a history of tumor progression or persistent disease or failure to achieve complete response following standard therapy.
• Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive MIBG or PET scans) or measurable (CT, MRI) disease documented after completion of prior systemic therapy.
• Disease staging approximately within one month of treatment.
• Human anti-mouse antibody (HAMA) titer <1000 Elisa units/ml if applicable
• Available autologous stem cells: ≥2 x 106 CD34+ cells/kg
• Adequate cardiac function as measured by echocardiogram
• Eligible NK donor
• Signed informed consent indicating awareness of the investigational nature of this program.

Donor Eligibility

• Donor is blood-related and HLA-haploidentical to the recipient.
• Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors. Tests include but are not limited to: HepBsAg, HepBsAb, HepBcAb, HepC antibody, HIV, HTLV I and II, VZV, CMV and VDRL, West Nile Virus and Chagas screen. Donor must have normal negative test results for HIV, HTLV I and II, and West Nile Virus. Donor exposure to other viral pathogens will be discussed on a case-by-case basis by the investigators.
• Donor must be able to undergo leukopheresis for total volume of 10-15 liters.
• There is no age restriction for the donor.

Exclusion criteria

• Patients with CR/VGPR disease
• Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity > or = to grade 3 except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from TPN, which may be grade 3
• ANC should be >500/uL; platelet count >25K/uL.
• History of allergy to mouse proteins
• Active life-threatening infection
• HAMA titer >1000 Elisa units/ml
• Inability to comply with protocol requirements

Donor Exclusion Criteria

• Cardiac risk factors precluding ability to undergo leukopheresis
• Concurrent malignancy or autoimmune disease
• Donor is pregnant.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

71 participants in 1 patient group

chemotherapy, allogeneic NK cells, 3F8

Experimental group

Description:

This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.

Treatment:

Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8